Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer
NCT07663513Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Apr 2029
- Countries
- 1
- Sponsor
- Fudan University
- Conditions
- ovarian cancer
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in ovarian cancer, sponsored by Fudan University. Primary endpoint: R0 resection rate up to 2 years. Planned start Jul 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental Arm
Iparomlimab and Tuvoraleimab injection + Bevacizumab + Paclitaxel + Carboplatin
03
Who it enrols
Female patients aged 18-75 with previously untreated, unresectable FIGO stage III-IV high-grade serous ovarian, fallopian tube, or primary peritoneal cancer, ECOG 0-1, adequate organ function, and no prior anti-tumor therapy.
04
Endpoints
Primary
R0 resection rate
Secondary
Objective response rate
Pathological complete response
Progression-Free Survival
Overall Survival
Treatment-related adverse events
Beyond the preview
Go deeper on NCT07663513.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663513.